Due to increasing average life expectancy, along with the high incidence of cardiovascular disease in aging, more than half of all cardiovascular procedures are performed in adults over 65 years of age. However, despite overall favorable safety profiles, older adults have an increased susceptibility to adverse outcomes. Indeed, exposure to cardiovascular procedures intended to promote survival may instead precipitate long-term disease and disability. A better understanding of resilience and vulnerability (i.e. why some individuals successfully navigate health stressors while others do not) may help identify physiologic factors that affect recovery potential and long-term wellbeing. The goal of this work is to take the first steps in identifying a potentially modifiable molecular indicator of vulnerability in patients with cardiovascular disease. Transcatheter aortic valve replacement (TAVR) is a minimally invasive alternative to surgical aortic valve replacement for those with symptomatic severe aortic stenosis (AS). Although over 70% of TAVR patients achieve improved quality of life (QoL) and prolonged survival, poor outcomes such as mortality and functional decline remain common. Clinical factors like the burden of cardiovascular disease, comorbidities, and frailty predict worse outcomes. Furthermore, preliminary data suggests that increased markers of inflammation and dysregulated immune activity are associated with worse outcomes, as well. A better understanding of the relationship between inflammatory and immune activity and outcomes after TAVR may point to mechanisms mediating vulnerability and suggest targets for intervention. Relevant to this, although never before explored in relation to cardiovascular procedures, a specific gene expression pattern known as the conserved transcriptional response to adversity (CTRA) is associated with adverse outcomes after exposure to a health stressor. Defined by the simultaneous upregulation of inflammation and downregulation of innate immune responses, CTRA expression prior to health-stress exposure predicts adverse events such as poor QoL and mortality. Importantly, CTRA expression is modifiable, and pharmacologic and behavioral interventions that successfully downregulate CTRA are associated with improved clinical outcomes. Therefore, this project explores the hypothesis that increased CTRA expression at baseline, as a marker of inflammatory and immune system dysfunction, will predict adverse long-term outcomes after TAVR. By identifying gene expression patterns that relate to increased vulnerability, the results will provide a foundation for future work exploring physiologic mechanisms that contribute to diminished resilience, and highlight potential targets for therapeutic manipulation to optimize outcomes. Furthermore, this project will support my professional development through mentored acquisition of research and leadership skills necessary to become a successful independent researcher with a transdisciplinary approach to understanding healthful aging in older adults with cardiovascular disease.

Public Health Relevance

Although an increased number of older adults are undergoing cardiovascular procedures designed to prolong survival and improve quality of life, poor outcomes such as functional decline and mortality remain common. This study explores the hypothesis that a modifiable pattern of unfavorable inflammatory and immune system gene expression predicts vulnerability to adverse long-term clinical outcomes after a cardiovascular procedure. Ultimately, this work will lead to a better understanding of resilience and vulnerability (i.e. why some individuals successfully navigate health stressors while others do not) in older adults by pointing to mechanisms mediating vulnerability and highlighting targets for intervention.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Small Research Grants (R03)
Project #
1R03AG064319-01
Application #
9811532
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Salive, Marcel
Project Start
2019-08-01
Project End
2021-03-31
Budget Start
2019-08-01
Budget End
2020-03-31
Support Year
1
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095